Business
Statement: Zantac Litigation Update BC Canada
Statement: Zantac Litigation Update BC Canada.
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 12 May 2023, London UK\n \nStatement: Zantac (ranitidine) litigation\n \n \n\nGSK plc (LSE/NYSE: GSK) welcomes the decision of the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795, dismissing a proposed class action on behalf of a class of ranitidine users in Canada.\n \nSince 2019 there have been 13 peer-reviewed epidemiological studies conducted looking at human data regarding the use of ranitidine. The decision recognises that after more than three years of extensive study, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk for any type of cancer.\n \nThe Court stated: \"Given the uncontroverted evidence that neither ranitidine nor NDMA are reliably associated with increased cancer risk, and the absence of evidence that ranitidine or NDMA cause cancer in humans, the plaintiff has failed to raise a bona fide triable issue regarding injury due to the ingestion and/or purchase of ranitidine.\"\n \nGSK will continue to vigorously defend proposed class actions by ranitidine users that have been filed in Ontario and Quebec as well as individual actions filed by ranitidine users in Canada.\n \nAbout GSK\nGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.\n \n\n\n\n\nGSK enquiries\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedia:\n\n\nTim Foley\n\n\n+44 (0) 20 8047 5502\n\n\n(London)\n\n\n\n\n\n\n\nDan Smith\n\n\n+44 (0) 20 8047 5502\n\n\n(London)\n\n\n\n\n\n\n\nKathleen Quinn\n\n\n+1 202 603 5003\n\n\n(Washington DC)\n\n\n\n\n\n\n\nLyndsay Meyer\n\n\n+1 202 302 4595\n\n\n(Washington DC)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nInvestor Relations:\n\n\nNick Stone\n\n\n+44 (0) 7717 618834\n\n\n(London)\n\n\n\n\n\n\n\nJames Dodwell\n\n\n+44 (0) 20 8047 2406\n\n\n(London)\n\n\n\n\n\n\n\nMick Readey\n\n\n+44 (0) 7990 339653\n\n\n(London)\n\n\n\n\n\n\n\nJosh Williams\n\n\n+44 (0) 7385 415719\n\n\n(London)\n\n\n\n\n\n\n\nCamilla Campbell\n\n\n+44 (0) 7803 050238\n\n\n(London)\n\n\n\n\n\n\n\nSteph Mountifield\n\n\n+44 (0) 7796 707505\n\n\n(London)\n\n\n\n\n\n\n\nJeff McLaughlin\n\n\n+1 215 751 7002\n\n\n(Philadelphia)\n\n\n\n\n\n\n\nFrannie DeFranco\n\n\n+1 215 751 4855\n\n\n(Philadelphia)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\...